Comparing the current results to its competitors, Autolus Therapeutics Plc reported Revenue increase in the 2 quarter 2026 by 118.37 % year on year, while most of its competitors have experienced contraction in revenues by -12.42 %, achieved in the same quarter.
Autolus Therapeutics Plc's Comment on Competition and Industry Peers
The competitive landscape for AUCATZYL includes two approved autologous CAR T-cell therapies for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL): Tecartus and Kymriah. Tecartus is approved for adult B-ALL patients, while Kymriah is approved for adolescents and young adults up to age 25. Potential competitors also include other autologous CAR T-cell products and allogeneic "off-the-shelf" CAR T-cell therapies. Allogeneic therapies, which are not derived from the patient's own cells, may offer more convenient delivery without manufacturing delays but have not demonstrated comparable durable efficacy and may require repeat dosing. Additional competition arises from other therapeutic classes such as bispecific T-cell engagers, antibody-drug conjugates, antibody treatments, and small molecule anti-tumor agents. These therapies are often initially studied and approved for relapsed or refractory patients and may be used in combination regimens over time.
Due to outstanding performance in Overall company, revenue grew by 118.37 % Autolus Therapeutics Plc improved its market share, to approximately 19.34 %.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Fate Therapeutics Inc's business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.
Curis Inc's business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.
C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid™ platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body's natural protein degradation machinery.
Sources:
Autolus Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Autolus Therapeutics Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
